Ascendis Pharma A/S (ASND): Price and Financial Metrics
ASND Price/Volume Stats
| Current price | $107.69 | 52-week high | $127.77 |
| Prev. close | $108.80 | 52-week low | $64.33 |
| Day low | $106.49 | Volume | 1,471,600 |
| Day high | $111.41 | Avg. volume | 465,425 |
| 50-day MA | $93.56 | Dividend yield | N/A |
| 200-day MA | $93.62 | Market Cap | 6.21B |
ASND Stock Price Chart Interactive Chart >
Ascendis Pharma A/S (ASND) Company Bio
Ascendis Pharma A/S is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of best-in-class therapeutics that address significant unmet medical needs. The company was founded in 2006 and is based in Hellerup, Denmark.
Latest ASND News From Around the Web
Below are the latest news stories about ASCENDIS PHARMA A that investors may wish to consider to help them evaluate ASND as an investment opportunity.
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan– Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan – Ascendis Pharma is eligible to receive $70 million upfront, development/regulatory milestones of up to $175 million, transfer pricing, and commercial milestones – Ascendis Pharma is also eligible to receive royalties on net sales in Japan, of up to mid-20’s percent, varying by product COPENHAGEN, Denmark, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasd |
Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism- YORVIPATH (developed as TransCon PTH) is a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism - Ascendis plans its first EU launch of YORVIPATH in Germany in January 2024 COPENHAGEN, Denmark, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Commission (EC) has granted marketing authorization for YORVIPATH® (palopegteriparatide) as replacement therapy indicated for the treatmen |
Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDACOPENHAGEN, Denmark, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has resubmitted its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adults with hypoparathyroidism to the U.S. Food & Drug Administration (FDA). The resubmission follows the Type A meeting held with the FDA in late August. “Research has shown that parathyroid hormone (PTH) replacement therapy is the ideal treatment for patients living with the s |
Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call TranscriptAscendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript November 7, 2023 Ascendis Pharma A/S misses on earnings expectations. Reported EPS is $-2.88 EPS, expectations were $-2.63. Operator: Hello, and welcome to Ascendis Pharma Third Quarter 2023 Earnings Conference Call and Webcast. Following the prepared remarks, there will be a question-and-answer period, instructions will be […] |
Ascendis Pharma Reports Third Quarter 2023 Financial ResultsEuropean Commission decision for TransCon™ PTH expected this month; if approved, first European Union launch planned in Germany in January 2024TransCon PTH NDA resubmission to FDA expected before mid-NovemberCompleted enrollment in the Phase 3 ApproaCH Trial; initiated TransCon CNP infant trial in the third quarter 2023; expect to initiate combination trial of TransCon CNP and TransCon hGH in the fourth quarter 2023 SKYTROFA Q3 revenue of €47.0 million, increasing full year 2023 SKYTROFA revenue |
ASND Price Returns
| 1-mo | 16.97% |
| 3-mo | 10.36% |
| 6-mo | 15.49% |
| 1-year | -8.01% |
| 3-year | -38.04% |
| 5-year | 70.94% |
| YTD | -11.82% |
| 2022 | -9.22% |
| 2021 | -19.34% |
| 2020 | 19.88% |
| 2019 | 122.06% |
| 2018 | 56.39% |
Continue Researching ASND
Want to see what other sources are saying about Ascendis Pharma A's financials and stock price? Try the links below:Ascendis Pharma A (ASND) Stock Price | Nasdaq
Ascendis Pharma A (ASND) Stock Quote, History and News - Yahoo Finance
Ascendis Pharma A (ASND) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...